Magdalini Migkou
Athens, ESYE31, Greece
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 113 publications
The prognostic value of red blood cell distribution width in AL amyloidosis.
Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: May 16, 2026
Management and long-term haematological and neurological outcomes of Immunoglobulin M and Waldenström's macroglobulinaemia-related neuropathy: A single-centre experience.
Journal: British journal of haematology
Published: April 27, 2026
Incidence of second primary malignancies in patients with AL amyloidosis and the impact of disease stage and therapies.
Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: April 01, 2026
A Prospective Study of Familial Predisposition in Plasma Cell Dyscrasias.
Journal: Blood advances
Published: March 11, 2026
Validation of the new IMS/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients.
Journal: HemaSphere
Published: March 09, 2026
Can Exercise Training Improve the Quality of Life and Physical Function in Multiple Myeloma Patients?: Discussing the Progression of the Training Stimulus.
Journal: Sports (Basel, Switzerland)
Published: December 18, 2025
Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathies.
Journal: British journal of haematology
Published: November 25, 2025
Clinical outcomes in newly diagnosed patients with Waldenström's macroglobulinaemia treated in a tertiary academic centre.
Journal: British journal of haematology
Published: September 15, 2025
Bone disease burden does not impact overall survival in newly diagnosed patients with multiple myeloma - a single center, retrospective imaging analysis on 119 patients.
Journal: Journal of bone oncology
Published: August 04, 2025
Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Experience.
Journal: Clinical lymphoma, myeloma & leukemia
Published: May 06, 2025
Last Updated: 09/26/2026